Novo Nordisk (NYSE:NVO) presented exploratory analyses from the STEP UP program showing that Wegovy (semaglutide) was associated with reductions in liver fat among adults with obesity who did not have diabetes.
Novo Nordisk (NYSE:NVO) launched a corporate rebrand that will see the company use the shorter “Novo” name in day-to-day communications while retaining Novo Nordisk A/S as its legal name.
Novo Nordisk (NYSE:NVO) and Anthropic announced a collaboration to apply Anthropic’s Claude AI models, including Claude Science, across Novo Nordisk’s research and development and software engineering activities.
Novo Nordisk (NYSE:NVO) reported phase 3 topline results showing once-weekly CagriSema achieved weight loss and blood sugar reductions in adults with type 2 diabetes and obesity.
Novo Nordisk (NYSE:NVO) agreed to license Hengrui Pharma’s phase 1-ready oral candidate HRS-1596 in a transaction valued at up to $2.6 billion.
